Read More

Scilex Holding Company Announces Results From Market Research With Rheumatologists Reveal A High Degree Of Interest In Gloperba As A Liquid Colchicine Formulation Designed For Precision Dosing

Gloperba® is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.Gout is a painful arthritic disorder affecting an estimated 9.2

SCLX

Read More

Veru To Host Investor Call On January 4th, 2024 To Discuss Recent Financing And Strategy To Prioritize The Development Of Enobosarm As A Combination Treatment To Prevent Muscle Loss And Augment Fat Loss Associated With Weight Loss GLP-1 Drugs

Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of obesity, oncology, and viral induced acute respiratory distress syndrome, today

VERU

Read More

Cellectar Biosciences Expands A New Licensing Agreement With The Wisconsin Alumni Research Foundation For Intellectual Property That Was The Result Of Collaborative Research With Iopofosine I 131 In Pediatric Cancers

Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced a new licensing

CLRB